At OmniSeq®, our mission since 2015 has been simple: To help each cancer patient find and access the drug or trial that’s right for them. We do this through molecular sequencing and first-of-its-kind comprehensive immune profiling, as well as pharmaceutical services.

Through a collaboration with LabCorp®, we created and launched OmniSeq INSIGHT℠, OmniSeq Advance℠,  OmniSeq Comprehensive® and MSI NGS℠. These innovative tools – which will be offered exclusively to U.S.-based physicians by Integrated Oncology, a member of the LabCorp Specialty Testing Group, and biopharmaceutical customers globally through Covance Drug Development – enable medical professionals to identify appropriate treatments specific to a patient’s cancer and immune profile.

A complete testing portfolio powered by precision medicine.

For Genomic & Immune Profiling

OmniSeq INSIGHTSM is a comprehensive, tissue-based, next generation sequencing genomic profiling device clinically and analytically validated for all solid tumors. The test is designed to detect genomic variants, signatures, and immune gene expression to provide physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options based on an individual genomic profile of each patient.

For Genomic & Immune Profiling

Comprehensive immune and genomic profiling to inform the therapeutic management of cancer patients with advanced solid tumors under consideration for checkpoint inhibition or targeted therapy. Measure the most significant protein, RNA and DNA biomarkers with a single order. Compare the relative effectiveness of personalized treatments based on curated and summarized evidence from our Pathologists.

For Targeted Therapy

Our goal was to create the most clinically-actionable molecular test of tumors possible. The result is OmniSeq Comprehensive®, a next-generation molecular sequencing assay that tests a tumor’s DNA and RNA to identify somatic variants – those genetic alterations caused by your cancer that are associated with response to particular drugs – in 144 genes. We believe that the importance of a patient’s tumor biopsy cannot be overstated, and Omniseq Comprehensive® was created to treat it as such.

For Microsatellite Instability

OmniSeq MSI NGS delivers microsatellite instability results from tumor only FFPE samples and eliminates the hassle to acquire and track matched normal DNA from tissue or blood. This test can be used to identify appropriate patients for KEYTRUDA®, regardless of histology. Omniseq MSI NGS is also cost equivalent to PCR, with similar turnaround times.

A complete testing portfolio powered by precision medicine.

For Genomic & Immune Profiling

OmniSeq INSIGHTSM is a comprehensive, tissue-based, next generation sequencing genomic profiling device clinically and analytically validated for all solid tumors. The test is designed to detect genomic variants, signatures, and immune gene expression to provide physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options based on an individual genomic profile of each patient.

For Genomic & Immune Profiling

Comprehensive immune and genomic profiling to inform the therapeutic management of cancer patients with advanced solid tumors under consideration for checkpoint inhibition or targeted therapy. Measure the most significant protein, RNA and DNA biomarkers with a single order. Compare the relative effectiveness of personalized treatments based on curated and summarized evidence from our Pathologists.

For Targeted Therapy

Our goal was to create the most clinically-actionable molecular test of tumors possible. The result is OmniSeq Comprehensive®, a next-generation molecular sequencing assay that tests a tumor’s DNA and RNA to identify somatic variants – those genetic alterations caused by your cancer that are associated with response to particular drugs – in 144 genes. We believe that the importance of a patient’s tumor biopsy cannot be overstated, and Omniseq Comprehensive® was created to treat it as such.

For Microsatellite Instability

OmniSeq MSI NGS delivers microsatellite instability results from tumor only FFPE samples and eliminates the hassle to acquire and track matched normal DNA from tissue or blood. This test can be used to identify appropriate patients for KEYTRUDA®, regardless of histology. Omniseq MSI NGS is also cost equivalent to PCR, with similar turnaround times.